These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 4015069)

  • 1. In vitro activity of Sch 34343 and cefbuperazone against anaerobic bacteria.
    Shafran SD; Wong J; Chow AW
    Antimicrob Agents Chemother; 1985 May; 27(5):749-52. PubMed ID: 4015069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of cefbuperazone, a new cephamycin, against anaerobic bacteria.
    Prabhala RH; Thadepalli H; Rao B; Bansal MB; Marshall R
    Antimicrob Agents Chemother; 1985 Apr; 27(4):640-2. PubMed ID: 4004195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activity of cefbuperazone against anaerobic bacteria isolated from community hospitals.
    Goldstein EJ; Citron DM
    Antimicrob Agents Chemother; 1985 Feb; 27(2):162-6. PubMed ID: 3985600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of cefbuperazone against anaerobic bacteria.
    Wexler H; Carter WT; Harris BH; Finegold SM
    Antimicrob Agents Chemother; 1985 Apr; 27(4):674-6. PubMed ID: 3847274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of cefotetan against anaerobic bacteria.
    Dias MB; Jacobus NV; Tally FP; Gorbach SL
    Diagn Microbiol Infect Dis; 1986 Apr; 4(4):359-63. PubMed ID: 3457672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of cefbuperazone against Bacteroides spp.
    Dias MB; Jacobus NV; Gorbach SL; Tally FP
    Antimicrob Agents Chemother; 1985 Jun; 27(6):968-70. PubMed ID: 4026272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of anaerobic bacteria to Sch 34343 and other antibiotics.
    Glupczynski Y; Gordts B; van der Linden MP; Labbé M; Yourassowsky E; Butzler JP
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():193-8. PubMed ID: 4030548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of cefmetazole against anaerobic bacteria.
    Cornick NA; Jacobus NV; Gorbach SL
    Antimicrob Agents Chemother; 1987 Dec; 31(12):2010-2. PubMed ID: 3481541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of anaerobic bacteria to Sch 34343 and other beta-lactam antibiotics.
    Jacobus NV; Tally FP; Gorbach SL
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():189-91. PubMed ID: 4030547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BMY28142, cefbuperazone (T-1982), and Sch 34343. Antimicrobial activity against 94 anaerobes compared to seven other antimicrobial agents.
    Jones RN; Barry AL; Packer RR
    Diagn Microbiol Infect Dis; 1985 May; 3(3):263-8. PubMed ID: 3838925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.
    Citron DM; Appleman MD
    Antimicrob Agents Chemother; 2001 Jan; 45(1):345-8. PubMed ID: 11120995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of cefbuperazone compared with that of other new beta-lactam agents against anaerobic gram-negative bacilli and contribution of beta-lactamase to resistance.
    Del Bene VE; Carek PJ; Twitty JA; Burkey LJ
    Antimicrob Agents Chemother; 1985 May; 27(5):817-20. PubMed ID: 3874597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in-vitro activity of Sch 34343 and other antimicrobial agents against anaerobic bacteria.
    Nord CE; Olsson-Liljequist B
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():183-8. PubMed ID: 2863246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vitro activities of sulopenem, a new parenteral penem, against anaerobes].
    Watanabe K; Kato N; Tanaka-Bandoh K; Tanaka Y; Kato H; Ueno K
    Jpn J Antibiot; 1996 Apr; 49(4):367-76. PubMed ID: 8786627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
    Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
    J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-formimidoyl thienamycin (MK0787): in vitro activity against anaerobic bacteria.
    Martin DA; Sanders CV; Marier RL
    Antimicrob Agents Chemother; 1982 Jan; 21(1):168-9. PubMed ID: 6952818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in-vitro activity of Sch 34343 for a wide spectrum of clinically significant anaerobic bacteria.
    Wells CL; Wilkins TD
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():177-82. PubMed ID: 4030546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of flomoxef compared to moxalactam, cefoxitin, cefotaxime, and clindamycin against anaerobes.
    Werner H; Heizmann W; Luft G
    Arzneimittelforschung; 1988 Nov; 38(11):1553-6. PubMed ID: 3214438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European collaborative study of reproducibility of quantitative sensitivity testing of anaerobes.
    King A; Phillips I
    J Antimicrob Chemother; 1988 Apr; 21(4):425-38. PubMed ID: 3378957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan.
    Teng LJ; Hsueh PR; Tsai JC; Liaw SJ; Ho SW; Luh KT
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2908-13. PubMed ID: 12183246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.